Get Real Stocks

AVTX · Avalo Therapeutics

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Country
United States

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

24h Volume by Exchange

No Data Yet

Issuer
Price
$7.45
24h Volume
-
Depth (±1%)
-